Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2021-09-20 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - PXS 9 pages 35.0KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options and convertible securities into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and the nature of the securities (employee incentive scheme options exercised). This is a formal announcement related to changes in the company's capital structure, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion, but rather a capital market update regarding securities issuance and quotation. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive update on capital changes.
2021-09-20 English
Application for quotation of securities - PXS 6 pages 27.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and the nature of the securities (employee incentive scheme options exercised). There is no financial performance data, earnings information, or management discussion. The document is an announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. This fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief notice but a detailed application for quotation, supporting the SHA classification.
2021-09-19 English
Notification of cessation of securities - PXS 4 pages 24.3KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of performance rights securities for PHARMAXIS LTD. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's issued securities, specifically the cessation of certain securities due to conditions not being met. It does not contain financial statements, management discussion, or detailed financial results. It is not a full report but a regulatory announcement about securities changes. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-09-19 English
Application for quotation of securities - PXS 6 pages 27.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and the nature of the securities (employee incentive scheme options exercised). This is a formal announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion, but rather a capital market announcement about share issuance and quotation. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is a full announcement, not just a brief notice or regulatory filing.
2021-09-08 English
Investor Presentation 19 pages 1.6MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation | 7 September 2021' and contains detailed information about the company's clinical programs, financial position, capital structure, management team, and strategic plans. It includes forward-looking statements, pipeline updates, clinical trial designs, and market opportunities. The content is typical of a presentation aimed at investors to provide an overview of the company's business, financials, and future prospects. There is no indication that this is a formal regulatory filing like an annual report, earnings release, or audit report. The length (15,000 characters) and detailed content support that this is a full investor presentation rather than a brief announcement or report publication notice. Therefore, the document best fits the category of Investor Presentation (IP).
2021-09-06 English
Pharmaxis Treatment to Prevent Wound and Burns Scars Clears 2 pages 132.5KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 31 August 2021 from Pharmaxis Ltd announcing positive Phase 1 clinical trial results for a topical drug treatment to prevent wound and burn scars. It discusses the trial details, future plans for further studies, and background information about the company and its drug development pipeline. There are no financial statements, regulatory filings, or detailed financial performance data. The document is a corporate announcement focused on clinical trial progress and drug development updates, not a financial report or regulatory filing. It is not an earnings release, annual report, or interim report. It is also not related to board changes, voting results, or capital changes. The content fits best as a general regulatory announcement or corporate update. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (7390 characters) and content confirm it is not a brief report publication announcement or a certification letter.
2021-08-30 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.